Información:
Error:
ID
34565
Descripción
Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone; ODM derived from: https://clinicaltrials.gov/show/NCT01516424
Link
https://clinicaltrials.gov/show/NCT01516424
Palabras clave
Versiones (1)
- 19/1/19 19/1/19 -
Titular de derechos de autor
see on clinicaltrials.gov
Subido en
19 de enero de 2019
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility Schizophrenia NCT01516424
Eligibility Schizophrenia NCT01516424
- StudyEvent: Eligibility
Similar models
Eligibility Schizophrenia NCT01516424
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
ID.1
Item
subject met dsm-iv-tr criteria for a primary diagnosis of schizophrenia
boolean
ID.2
Item
patients are 18≤age≤65 years of age on the day when informed consent is obtained.
boolean
ID.3
Item
subject had a panss total score ≥70 and 120≥ at screening
boolean
ID.4
Item
subject had a score ≥4 on the panss at screening and baseline.
boolean
ID.5
Item
subjects are willing and able to comply with study protocol including treatment in hospital.
boolean
ID.6
Item
subjects or their legal guardians have signed the written informed consent form.
boolean
ID.7
Item
the subject was treatment with other investigate product within 30 days.
boolean
ID.8
Item
subject had a history of treatment with long-acting drug for anti schizophrenia within 56 days.
boolean
ID.9
Item
subject had a history of treatment with clozapine within 28 days.
boolean
ID.10
Item
subject with parkinson disease,etc
boolean